Ropinirole hydrochloride for amyotrophic lateral sclerosis: A single-center, randomized feasibility, double-blind, placebo-controlled trial - Morimoto, Satoru; Takahashi, Shinichi; Ito, Daisuke; Daté, Yugaku; Okada, Kensuke; Chyi, Chai Muh; Nishiyama, Ayumi; Suzuki, Naoki; Fujimori, Koki; Takao, Masaki; Hirai, Miwa; Kabe, Yasuaki; et al. (medRxiv, 2021)
Background We previously used an induced pluripotent stem cell-based drug repurposing approach to demonstrate that ropinirole hydrochloride (ropinirole) attenuated amyotrophic lateral sclerosis (ALS)-specific pathological phenotypes. Here, we assessed the safety and feasibility of ropinirole in ALS patients to verify its efficacy.Methods We conducted a randomized feasibility trial of ALS. Twenty participants with ALSFRS-R scores greater than 2 points were randomly assigned using dynamic allocation to receive ropinirole or placebo for 24 weeks in the double-blind period. Upon completion, participants could choose to participate in the following 24-week open-label active extension period. The primary outcomes were safety and tolerability. The secondary outcomes for the feasibility trial objective were the change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score, composite functional endpoint, combined assessment of function and survival, event-free survival, and time to ≤50% forced vital capacity (blinded outcome assessment). This study is registered with the UMIN Clinical Trials Registry, UMIN000034954.Findings Twenty-one participants were randomized into two groups (ropinirole group; n=14) and received ropinirole (n=13) or placebo (n=7) and the data of all participants were analysed using mixed-effects models for repeated measures together. Overall, the incidences of adverse events, most of which had been reported previously, were similar within both groups. Notably, the incidence of gastrointestinal disorders (mainly, temporary mild nausea and diarrhoea) was high at 76·9% in the ropinirole group (14·3% in the placebo group). Regarding the feasibility of verifying efficacy, there were no significant differences in the ALSFRS-R score and combined assessment of function and survival scores during the double-blind period for 6 months, while the participants in the ropinirole group had lived an additional 27·9 weeks without disease progression events compared with the placebo group (log-rank test, 95% confidence interval, 4·3–37·4) at 12 months (secondary outcome).Interpretation Ropinirole is safe and tolerable for patients with ALS and this trial indicates feasibility for a subsequent large-scale trial.Funding This study was funded by The Japan Agency for Medical Research and Development and K Pharma Inc.Competing Interest StatementDr. Morimoto reports grants from Keio University School of Medicine, during the conduct of the study. Dr. Takahashi reports grants from Keio University School of Medicine, during the conduct of the study. Dr. Ito has nothing to disclose. Dr. Daté has nothing to disclose. Dr. Okada has nothing to disclose. Dr. Chai has nothing to disclose. Dr. Nishiyama has nothing to disclose. Dr. Naoki Suzuki has nothing to disclose. Dr. Fujimori reports personal fees from Sumitomo Dainippon Pharma Co., Ltd., outside the submitted work. Dr. Takao has nothing to disclose. Ms. Hirai has nothing to disclose. Dr. Kabe has nothing to disclose. Dr. Suematsu has nothing to disclose. Dr. Jinzaki has nothing to disclose. Dr. Aoki reports grants from Research on Nervous and Mental disorders, Research on rare and intractable diseases, Research on Psychiatric and Neurological Diseases and Mental Health from the Japanese Ministry of Health Labour and Welfare, Grants-in-Aids for Scientific Research, an Intramural Research Grant for Neurological Psychiatric Disorders from NCNP, Grants-in-Aids for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT), and Practical Research Project for Rare / Intractable Diseases from Japan Agency for Medical Research and Development (AMED), during the conduct of the study. Mr. Fujiki has nothing to disclose. Dr. Sato has nothing to disclose. Dr. Suzuki has nothing to disclose. Dr. Nakahara reports grants from Japan Agency for Medical Research and Development (AMED), grants from K Pharma, Inc, non-financial support from GSK, during the conduct of the study. Dr. Okano reports grants from Japan Agency for Medical Research and Development, grants and personal fees from K Pharma Inc., during the conduct of the study; personal fees from SanBio Co.Ltd., personal fees from Regenerative Medicine iPS Gateway Centre Co.,Ltd., outside the submitted work; In addition, Dr. Okano has a patent THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AND COMPOSITION FOR TREATMENT licensed to K Pharma Inc. and grant support from AMED (The Acceleration Program for Intractable Disease Research Utilizing Disease-specific iPS Cells (Grant No. JP 19bm0804003, JP 20bm0804003, JP 21bm0804003) and Research on Practical Application of Innovative Pharmaceutical and Medical Devices for Rare and Intractable Diseases (Grant No. JP 18ek0109395, JP 19ek0109395, JP 20ek0109395, JP 18ek0109329, JP 19ek0109329, JP 20ek0109329). The human spinal cord samples were provided by Platform of Supporting Cohort Study and Biospecimen Analysis, Grant-in-Aid for Scientific Research on Innovative Areas―Platforms for Advanced Technologies and Research Resources, Ministry of Education, Culture, Sports, Science and Technology, Japan (Grant No. 16H06277) and Intramural Research Grant for Neurological Psychiatric Disorders from National Centre of Neurology and Psychiatry (NCNP).Clinical TrialUMIN000034954Funding StatementThis clinical trial was sponsored by K Pharma, Inc. The study drug, active drugs, and placebo were supplied free-of-charge by GlaxoSmithKline K.K.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Keio University Hospital gave ethical approval for this work (No. D18-01).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.